secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allakos Inc. (—)
CIK:        0001564824
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0000950170-25-008992
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allakos discontinues AK006 after Phase 1 CSU failure, cuts 75% of workforce
---------------------------------------------------------------------------

- AK006 Phase 1 CSU study failed: mean UAS7 change -8.2 (AK006) vs -12.4 (placebo); no therapeutic activity.
- Workforce reduction of ~75%; ~15 employees to explore strategic alternatives and wind-down trial.
- Restructuring costs estimated $34M-$38M, majority paid H1 2025; Dec 31, 2024 cash ~$81M; June 30, 2025 cash est. $35M-$40M.
- AK006 was well-tolerated with no serious adverse events, but showed no efficacy versus placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/0000950170-25-008992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/allk-20250127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-008992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer